Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.

NCT NCT03201445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03201445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
Lead sponsor
Lakefront Biotherapeutics NV
Phase
Phase 2
Overall status
Terminated
Start date
July 11, 2017
Completion date
October 24, 2023
Enrollment
139 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel disease